Dr. Jay S. Skyler is a Professor of Medicine, Pediatrics, & Psychology at the University of Miami, Miami, Florida, in the Division of Endocrinology, Diabetes, & Metabolism in the Department of Medicine, of which he was the Director from 2000 to 2004; and Deputy Director for Clinical Research and Academic Programs in the Diabetes Research Institute. For 22 years, Dr. Skyler also served as Study Chairman for the National Institute of Diabetes & Digestive & Kidney Diseases Type 1 Diabetes clinical trials network, conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. His research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention. He is widely acclaimed for developing "algorithms" for patient adjustment of insulin doses.
Dr. Skyler is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. He was founding Editor-in-Chief of Diabetes Care, and currently is Senior Editor of Diabetes Technology & Therapeutics.
He has a bachelor of science degree from Pennsylvania State University and a doctor of medicine degree from Jefferson Medical College. He served as an intern, resident, and fellow, and was on the faculty of Duke University.
What is Jay S. Skyler's net worth?
The estimated net worth of Jay S. Skyler is at least $67,014.00 as of June 22nd, 2021. Dr. Skyler owns 900 shares of DexCom stock worth more than $67,014 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Skyler may own. Learn More about Jay S. Skyler's net worth.
How do I contact Jay S. Skyler?
Has Jay S. Skyler been buying or selling shares of DexCom?
Jay S. Skyler has not been actively trading shares of DexCom during the past quarter. Most recently, Jay S. Skyler sold 20,000 shares of the business's stock in a transaction on Tuesday, June 22nd. The shares were sold at an average price of $426.37, for a transaction totalling $8,527,400.00. Following the completion of the sale, the director now directly owns 900 shares of the company's stock, valued at $383,733. Learn More on Jay S. Skyler's trading history.
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 9/9/2024.
